ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-pxliii.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-pxliii.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1053.xmlCrossing Over2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1053.pdf2026-04-18Crossing Overhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-pxxv.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-pxxv.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1066.xmlProlonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1066.pdf2026-04-18Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutationhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1061.xml HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1061.pdf2026-04-18 HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitorhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1054.xmlWas There a Patient in Your Clinic Today Who Was Distressed?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1054.pdf2026-04-18Was There a Patient in Your Clinic Today Who Was Distressed?https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1058.xmlNCCN: The Future is Bright2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1058.pdf2026-04-18NCCN: The Future is Brighthttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1079.xmlCancer-Associated Venous Thromboembolic Disease, Version 1.20152026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1079.pdf2026-04-18Cancer-Associated Venous Thromboembolic Disease, Version 1.2015https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1140.xmlAnaplastic Thyroid Carcinoma, Version 2.20152026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1140.pdf2026-04-18Anaplastic Thyroid Carcinoma, Version 2.2015https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1131.xmlRacial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1131.pdf2026-04-18Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Studyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1120.xmlGeriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1120.pdf2026-04-18Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Expertshttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1102.xmlEffectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1102.pdf2026-04-18Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiarieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1111.xmlReduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1111.pdf2026-04-18Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audithttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1097.xmlCalcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1097.pdf2026-04-18Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practicehttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1151.xmlSurvivorship in Non–Small Cell Lung Cancer: Challenges Faced and Steps Forward2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1151.pdf2026-04-18Survivorship in Non–Small Cell Lung Cancer: Challenges Faced and Steps Forwardhttps://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1163.xmlIt May Be Time to Abandon Urine Tests for Bladder Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/13/9/article-p1163.pdf2026-04-18It May Be Time to Abandon Urine Tests for Bladder Cancer